Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma

Department of Oncology, The Johns Hopkins University, Baltimore, MD.
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation (Impact Factor: 3.4). 01/2013; 19(4). DOI: 10.1016/j.bbmt.2013.01.006
Source: PubMed


BACKGROUND: The role of allogeneic blood or marrow transplantation (alloBMT) for peripheral T-cell lymphoma (PTCL) remains to be defined. There is growing interest in reduced-intensity conditioning (RIC) regimens and/or utilization of HLA-haploidentical (haplo) grafts given concerns about treatment-associated toxicities and donor availability. METHODS: We reviewed the outcomes of 44 consecutive, related donor alloBMTs for PTCL performed at Johns Hopkins Hospital from 1994-2011, including 18 RIC/haplo alloBMTs. RESULTS: Patients receiving RIC (n=24) were older with median age of 59 years (range 24-70) than patients receiving myeloablative conditioning (MAC, n=20) with median age of 46 years (range 18-64), p=0.01. The median age at RIC/haplo alloBMT was 60 years. The estimated 2-year progression-free survival (PFS) was 40% (95% confidence interval (CI) 26-55%) and overall survival (OS) was 43% (95% CI 28-59%). In older patients (> 60, n=14), the estimated 2-year PFS and OS were 38% (CI 18-79%) and 45% (CI 24-86%). On unadjusted analysis, there was a tendency towards superior outcomes for alloBMT in first remission versus beyond first remission, with an estimated 2-year PFS of 53% (95% CI 33-77%) versus 29% (95% CI 9-45%), p=0.08. On competing risk analysis, the 1-year cumulative incidence of relapse was 38% for MAC/HLA-identical alloBMTs and 34% for RIC/haplo alloBMTs. Estimated 1-year non-relapse mortality was 10% for MAC and 8% for RIC (11% for RIC/haplo alloBMT). On unadjusted landmark analysis, patients with acute grade II-IV or chronic GVHD had a 17% probability of relapse (95% CI 0-39%), compared to 66% (95% CI 48-84%) in patients without GVHD, p=0.04. CONCLUSIONS: Utilization of RIC and alternative donors expands treatment options in PTCL to those who are older and unable to tolerate high-dose conditioning, with outcomes comparable to approaches using myeloablative regimens and HLA-matched donors. AlloBMT may be appropriate in first remission in select high-risk cases.

35 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: T-cell non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that represent 10-15% of all NHL. The prognosis of relapsed T-cell NHL is poor, especially for those relapsing after an autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT). Disease relapse post auto-HCT is best managed on a clinical trial. In the absence of a investigational protocol, the choice of salvage therapies should take into account patient performance status, eligibility for an allo-HCT, and surface CD30 expression. CD30-directed therapies or aggressive salvage regimens can be used as a bridge to allo-HCT in medically fit patients. In the elderly or more infirm patients single-agent therapies could be offered, aiming at palliation. Similarly, relapse after an allo-HCT is not uncommon and is a real challenge. Reduction in ongoing immune suppression or donor lymphocyte infusion are often considered in this setting to augment graft-versus-lymphoma (GVL) effects and can occasionally provide durable disease control. Clinical trials designed to investigate novel therapeutic agents with immunomodulatory properties to augment GVL effects (e.g. HDAC inhibitors, proteasome inhibitor, lenalidomide) or targeted therapies (e.g. aurora A kinase inhibitors, ALK inhibitors) are sorely needed to improve the dismal outcomes of T-cell NHL relapsing after an allo-HCT.
    Seminars in Hematology 11/2013; 51(1). DOI:10.1053/j.seminhematol.2013.11.005 · 3.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral T-cell lymphomas (PTCL) are a diverse group of lymphoproliferative disorders, which share a common denominator of overall poor prognosis, with few exceptions. In this article, the authors review current standard of care approaches for the treatment of PTCLs, the role of stem-cell/bone marrow transplantation, and current developments in novel targeted therapies.
    Frontiers in Oncology 05/2013; 3:138. DOI:10.3389/fonc.2013.00138
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral T-cell lymphoma (PTCL) is comprised of a rare heterogeneous group of diseases with diverse clinical presentations; however outcomes associated with conventional chemotherapy are generally poor in the majority of patients. Newer approaches, which include dose-intensification and agents with novel mechanisms of action, are needed to improve outcomes in this group of patients. In this review we examine the results of two recent large Phase II trials with romidepsin, a histone deacetylase inhibitor which shows considerable activity and good tolerability in patients with T-cell lymphoma. These initial results observed with single-agent romidepsin provide a foundation for exploring combination strategies and demonstrates proof-of-principle that other such drugs with similar mechanisms of action may be effective in T-cell lymphoma.
    Expert Review of Hematology 08/2013; 6(4):351-9. DOI:10.1586/17474086.2013.814833 · 2.07 Impact Factor
Show more

Similar Publications